a6788f
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
Issued: 23 March 2022, London UK
ISSUANCE OF NOTES
GSK Consumer Healthcare Capital UK plc and GSK Consumer Healthcare
Capital NL B.V. (together with GSK Consumer Healthcare Capital UK
plc, the "EMTN Issuers") announce that, on 22 March 2022, they
successfully priced the following notes (the "EMTN Notes") under the GBP 10,000,000,000 Euro Medium Term
Note Programme of the EMTN Issuers:
-
GBP
300,000,000 2.875% Fixed Rate Senior Notes due 2028 and GBP
400,000,000 3.375% Fixed Rate Senior Notes due 2038, each issued
by GSK Consumer Healthcare Capital UK plc; and
-
EUR
850,000,000 1.250% Fixed Rate Notes due 2026, EUR 750,000,000
1.750% Fixed Rate Senior Notes due 2030 and EUR 750,000,000 2.125%
Fixed Rate Senior Notes due 2034, each issued by GSK Consumer
Healthcare Capital NL B.V.
In addition, GSK Consumer Healthcare Capital UK plc and GSK
Consumer Healthcare Capital US LLC announce that, on 21 March 2022,
they successfully priced the following notes (the
"144A
Notes") pursuant to an Offering
Memorandum dated 21 March 2022:
-
USD
700,000,000 3.024% Callable Fixed Rate Senior Notes due 2024, USD
300,000,000 Callable Floating Rate Senior Notes due 2024, USD
2,000,000,000 3.375% Fixed Rate Senior Notes due 2027, USD
1,000,000,000 3.375% Fixed Rate Senior Notes due 2029, USD
2,000,000,000 3.625% Fixed Rate Senior Notes due 2032 and USD
1,000,000,000 4.000% Fixed Rate Senior Notes due 2052, each issued
by GSK Consumer Healthcare Capital US LLC; and
-
USD
1,750,000,000 3.125% Fixed Rate Senior Notes due 2025 issued by GSK
Consumer Healthcare Capital UK plc.
The EMTN Notes and the 144A Notes (together, the
"Notes") will be guaranteed by GlaxoSmithKline plc up to
and excluding the Guarantee Assumption Date (as defined in the
Terms and Conditions of the Notes).
For further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
UK
Media enquiries:
|
David
Mawdsley Simon Steel
Tim
Foley
|
+44 (0)
20 8047 5502
+44 (0)
20 8047 5502
+44 (0)
20 8047 5502
|
(London)
(London)
(London)
|
|
|
|
|
European
Analyst/Investor enquiries:
|
James
Dodwell
Danielle
Smith
|
+44 (0)
20 8047 2406
+44 (0)
20 8047 0932
|
(London)
(London)
|
IMPORTANT DISCLAIMER: This announcement does not constitute an
offer of any securities for sale (including, without limitation,
any Notes). The offer and sale of the Notes may be restricted by
law in certain jurisdictions.
This document does not constitute, or form part of, an offer to
sell, or a solicitation of an offer to purchase, any securities in
the United States of America (including its territories and
possessions, any state of the United States of America and the
District of Columbia) (the "United States"). The securities
referred to herein have not been and will not be registered under
the U.S. Securities Act of 1933, as amended (the "Securities Act")
or under the securities laws of any state of the United States, and
may not be offered, sold, resold or delivered directly or
indirectly, in or into the United States or to a U.S. person absent
registration or an applicable exemption from, or in a transaction
not subject to, the registration requirements of the Securities
Act.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
23, 2022
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|